ELUTIA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.22 USD | -1.83% |
|
+15.00% | +49.07% |
| 05-09 | Elutia Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 05-09 | Earnings Flash (ELUT) ELUTIA Posts Q1 Revenue $6.7M, vs. Street Est of $6.1M | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +49.07% | 79.87M | D | ||
| +0.10% | 91.42B | A- | ||
| +3.16% | 41.08B | A- | ||
| -11.10% | 34.26B | B- | ||
| +53.99% | 25.27B | A | ||
| -9.41% | 12.81B | B- | ||
| -12.25% | 11.6B | D+ | ||
| -44.00% | 11.42B | B | ||
| +5.77% | 9.16B | B+ | ||
| -6.90% | 8.22B | B- |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ELUT Stock
- Ratings Elutia Inc.